Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
Description: Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3.This conversation focuses on specific reasons that initiating drug development in cirrhosis might offer unique benefits against the traditional model. Stephen Harrison starts off by discussing changing views of which cirrhosis patients are mostly likely to respond. After some comments from Louise Campbell about patient engagement, Stephen and Jörn Schattenberg discuss reasons that improvements in non-invasive testing, and particularly MR Elastography, might make cirrhosis the preferred target for drug de...